TY - JOUR
T1 - Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer
AU - Shariat, Shahrokh F.
AU - Marberger, Michael J.
AU - Lotan, Yair
AU - Sanchez-Carbayo, Marta
AU - Zippe, Craig
AU - Lüdecke, Gerson
AU - Boman, Hans
AU - Sawczuk, Ihor
AU - Friedrich, Martin G.
AU - Casella, Roberto
AU - Mian, Christine
AU - Eissa, Sanaa
AU - Akaza, Hideyuki
AU - Serretta, Vincenzo
AU - Huland, Hartwig
AU - Hedelin, Hans
AU - Raina, Rupesh
AU - Miyanaga, Naoto
AU - Sagalowsky, Arthur I
AU - Roehrborn, Claus
AU - Karakiewicz, Pierre I.
N1 - Funding Information:
Supported by the Austrian Program for Advanced Research and Technology (SFS), and Fonds de la Recherche en Santé du Québec, the CHUM Foundation, the Department of Surgery and Les Urologues Associés du CHUM (PIK).
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/9
Y1 - 2006/9
N2 - Purpose: We assessed variability in the diagnostic performance of NMP22® for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. Materials and Methods: NMP22® voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. Results: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22® was 5.5 U/ml (range across institutions 2.5 to 18.8). Of the patients 33.5% had grade III tumors (range across institutions 20.6% to 54.0%) and 22.4% had muscle invasive tumors (range across institutions 3.2% to 38.2%). Area under the ROC curve for bladder TCC detection was 0.735 (95% CI 0.715 to 0.755, range across institutions 0.676 to 0.889). The manufacturer recommended cutoff of 10 U/ml detected 57% of cases with a 19% false-positive rate. AUC for grade III and stage T2 or greater disease was 0.806 (95% CI 0.780 to 831) and 0.864 (95% CI 0.839 to 0.890), respectively. For each NMP22® cutoff NMP22® had higher sensitivity for detecting grade III and stage T2 or greater bladder transitional cell carcinoma than for detecting any cancer. No optimal cutoffs for detecting any or aggressive bladder transitional cell carcinoma could be derived based on NMP22® values. Conclusions: There is a substantial degree of heterogeneity in the diagnostic performance of NMP22® applied to populations from different institutions. There is no clearly defined NMP22® cutoff but there is a continuum of risk for recurrence and progression.
AB - Purpose: We assessed variability in the diagnostic performance of NMP22® for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. Materials and Methods: NMP22® voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. Results: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22® was 5.5 U/ml (range across institutions 2.5 to 18.8). Of the patients 33.5% had grade III tumors (range across institutions 20.6% to 54.0%) and 22.4% had muscle invasive tumors (range across institutions 3.2% to 38.2%). Area under the ROC curve for bladder TCC detection was 0.735 (95% CI 0.715 to 0.755, range across institutions 0.676 to 0.889). The manufacturer recommended cutoff of 10 U/ml detected 57% of cases with a 19% false-positive rate. AUC for grade III and stage T2 or greater disease was 0.806 (95% CI 0.780 to 831) and 0.864 (95% CI 0.839 to 0.890), respectively. For each NMP22® cutoff NMP22® had higher sensitivity for detecting grade III and stage T2 or greater bladder transitional cell carcinoma than for detecting any cancer. No optimal cutoffs for detecting any or aggressive bladder transitional cell carcinoma could be derived based on NMP22® values. Conclusions: There is a substantial degree of heterogeneity in the diagnostic performance of NMP22® applied to populations from different institutions. There is no clearly defined NMP22® cutoff but there is a continuum of risk for recurrence and progression.
KW - biological
KW - bladder
KW - bladder neoplasms
KW - nuclear matrix protein 22
KW - tumor markers
UR - http://www.scopus.com/inward/record.url?scp=33746678594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746678594&partnerID=8YFLogxK
U2 - 10.1016/j.juro.2006.04.017
DO - 10.1016/j.juro.2006.04.017
M3 - Article
C2 - 16890655
AN - SCOPUS:33746678594
SN - 0022-5347
VL - 176
SP - 919
EP - 926
JO - Journal of Urology
JF - Journal of Urology
IS - 3
ER -